

## **Therapixel announces fundraising of 15 M€ in series B to deploy MammoScreen® 2D/3D**

*The Company will accelerate the commercial deployment of its Artificial Intelligence reading solution for 2D/3D mammography, with a focus on the United States*

**Paris, Nice, and Chicago, 12 May 2022 - [Therapixel](#), designer and supplier of MammoScreen® an Artificial Intelligence software reading aid for mammography, announces today fundraising of 15 M€ in series B.**

This operation was led by Crédit Mutuel Innovation and CapHorn, joined by Verve, Sham Innovation Santé and historical investors Omnes, IT-Translation, M-Capital and Région Sud Investissement. This fundraising will enable Therapixel to accelerate its commercial presence in the United States, launch more unique features for MammoScreen, and push even further the boundaries of its intelligent reading aid for mammography.

Armed with two FDA regulatory clearances in the United States for both 2D and 3D (tomosynthesis) mammography, MammoScreen is already being deployed across large networks of breast cancer screening clinics. MammoScreen uses a unique score, MammoScreen Score™ to signal at a glance the level of suspicion of a mammogram. This allows to confirm the lesions that are certain and to save a precious time with a faster reading of benign cases. Thus, radiologists feel more confident in their decision and can spend more time on difficult cases that require more attention.

**Matthieu Leclerc-Chalvet, CEO of Therapixel** declares: *“We are very happy with the closing of this fundraising with investors active in the field of digital health. These funds will allow our American team to grow and to ramp up their activities to deliver an already well filed pipeline. We are now recruiting sales and support people to supplement our experienced team”*

**Pierre Fillard, Chief Scientific and Technology Officer and Founder of Therapixel** continues: *“This is a major step for Therapixel and I am proud of the achievements of our teams in collaboration with radiologists partners. We will accelerate the launch of a new generation of AI that will allow women to benefit from an earlier detection with less anxiety, radiologists to be assisted in the ever-growing demand for imaging, and to identify the regulatory and clinical developments that will maintain our position of solution of reference for radiologists reading mammography”*

**Jérôme Féraud, Directeur of healthcare investments and Tanguy Besson, Associate at Crédit Mutuel Innovation,** continue :



*“Beyond the technological performance of the solutions developed by Therapixel, it became obvious for us to support MammoScreen deployment that helps improve cancer detection, at a time when women are in a particularly stressful situation. The overall ergonomics of the solution brings the radiologists a valuable image analysis tool that allow them to optimize their time and focus their expertise on the specifics of the case.”*

**François Santi, Principal at CapHorn** continues :

*“We are very pleased to support Therapixel in this new round of strategic investment, in collaboration with a number of experienced investors in the field of digital health. We followed Therapixel for several months and were impressed by the capability of execution of the team and their achievements during this period. We are very happy to support Therapixel’s commercial expansion in the United States, and help the company establish a new standard in breast cancer detection.”*

With this new round, Therapixel has raised more than 20 M€ since its founding in 2013.

**The following council and advisor helped with this round:**

Legal counsel: JonesDay – Renaud Bonnet

Financial advisors: Fraser Finance – Olivier Koechlin and Deborah Herst

**Press contacts:**

Neliya Tumbava (Therapixel) - [media@therapixel.com](mailto:media@therapixel.com)

Louisa Mesnard (IT-Translation) - [lmesnard@elaia.com](mailto:lmesnard@elaia.com)

Véronique Richez-Lerouge (Crédit Mutuel Innovation) - [v.richez-lerouge@reso-media.com](mailto:v.richez-lerouge@reso-media.com)

Aurélien Blanchard-Massoni (Omnes Capital) [aurelie.blanchard-massoni@omnescapital.com](mailto:aurelie.blanchard-massoni@omnescapital.com)

Valérie Roché-Melin (Région Sud Investissement) – [v.roche@regionsudinvestissement.com](mailto:v.roche@regionsudinvestissement.com)

---

**About :**

**Therapixel** is a French company specialized in the design and commercialization of AI-powered medical imaging software, with the goal of delivering pertinent information at the right time to healthcare professionals. Winner of the [Digital Mammography DREAM Challenge](#) in 2017, the global competition on breast cancer detection with AI, Therapixel has developed MammoScreen®, a software that helps with the interpretation of screening 2D and 3D mammograms. With MammoScreen, even experienced radiologists can improve their performance, feel more confident in their judgment, and reassure women quicker. Find more at [www.mammoscreen.com](http://www.mammoscreen.com)



**CapHorn** is a Paris-based VC firm investing in innovative companies across Europe, focusing on Healthtech, Sustainability, and Enterprise software. We partner with outstanding entrepreneurs and commit investments from € 1M to € 15M in high growth companies, from early to late stage. CapHorn has an active portfolio of 50 companies and supports their development by leveraging its extensive network of business leaders. The firm, established in 2011, is part of the Anaxago Group.

CAPHORN: TRUST, FUNDING, NETWORK. Find more on: [caphorn.vc](http://caphorn.vc)

**Crédit Mutuel Innovation** is Credit Mutuel Equity (3.5 B€ managed capital) subsidiary specialized in venture capital investments. Crédit Mutuel Innovation invests its own funds in tickets of 1 to 20 M€, in innovative digital, life science and deeptech companies.

Crédit Mutuel Innovation allows entrepreneurs to develop their growth potential by connecting them to other companies in their ecosystems. Because it takes more than 5 years to create a global leader, Crédit Mutuel Innovation invests in the long term its own funds and builds long term relationships with the entrepreneurs it supports [www.creditmutuel-equity.eu](http://www.creditmutuel-equity.eu)

**Omnes** is a leading private equity and infrastructure investor. With over €5 billion in assets under management, it provides companies with the capital they need to fund their growth, in three key areas: venture capital, growth & buyout capital and infrastructure. Omnes is wholly owned by its employees. It is committed to ESG factors and has founded the Fondation Omnes to fund initiatives in favor of children and young people. It is a signatory to the United Nations Principles for Responsible Investment (PRI). [www.omnescapital.com](http://www.omnescapital.com)

**IT-Translation** is now part of Elaia. **Elaia** is a European top-tier VC firm with a strong tech DNA. We back tech disruptors with global ambition from early stage to growth development. For the past 20 years, our commitment has been to deliver high performance with values. We are proud to have been an active partner in over 100 startups including success stories such as Criteo (Nasdaq), Orchestra Networks (acquired by Tibco), Volterra (acquired by F5), Mirakl (valued \$3.5B in Series E) and Shift Technology (valued \$1B+ in Series D). Learn more <http://www.elaia.com> • [@ElaiPartners](https://twitter.com/ElaiPartners)

**M/Capital Partners** is a French asset management company which mobilizes mixed, private, and governmental funding to invest into companies and into real estate to foster the creation of new growing, resilient and inclusive values. M/Capital believes that entrepreneurs are in a unique position to transform the world we live in. Therefore, M/Capital backs men and women who work to empower people, to foster cohesion and to preserve our planet. M/Capital Group has more than €800 millions under management across four divisions (Real Estate, Venture Capital, Private Equity and Private Debt) and relies on 65 talents located in Paris, Toulouse, Marseille, Montpellier and Nice (France). [www.mcapital.fr](http://www.mcapital.fr)

**Région Sud Investissement** is the regional investment company created in 2010 by the South Region to support the emergence and development of growth companies. Région Sud Investissement, with a capital of €146M, receives 42% of its capacity from the European Union through the ERDF fund. It has invested in 335 companies so far and plans to launch a new equity fund called “RSI React Eu” for growth companies who were impacted by the sanitary crisis. [www.regionsudinvestissement.com](http://www.regionsudinvestissement.com)



